Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-05-25 Director's Dealing
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-05-25 English
SC 13D/A
Major Shareholding Notification
2024-05-07 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Werewolf Therapeutics, Inc. It specifically states in Item 2.02 that the company issued a press release announcing financial results for the quarter ended March 31, 2024, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3771 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. According to the rules, such a document that announces or furnishes a press release of financial results without including the full report should be classified as a Regulatory Filing (RNS).
2024-05-03 English
ARS
Annual Report
2024-04-12 English
DEFA14A
Remuneration Information Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text indicates it is a 'Definitive Additional Materials' filing related to a proxy statement for Werewolf Therapeutics, Inc. Proxy statements and related materials are classified under 'Remuneration Information' (DEF 14A) as they detail compensation and solicit shareholder votes. The document length is short and it is clearly a proxy statement filing, not an annual report or other financial report. Therefore, the correct classification is DEF 14A.
2024-04-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.